Cinctive Capital Management LP Has $1.93 Million Stake in DaVita Inc. $DVA

Key Points

• Cinctive Capital Management LP significantly reduced its holdings in DaVita Inc. by 72.8% during the first quarter, leaving them with 12,614 shares, valued at approximately $1.93 million.
• While Cinctive Capital trimmed its position, other investors, such as UMB Bank and National Pension Service, increased their stakes in DaVita significantly during the same period.
• DaVita reported earnings of $2.95 per share, exceeding analyst estimates, along with revenues of $3.38 billion for the quarter, indicating a growth of 6.1% compared to the previous year.

Cinctive Capital Management LP lessened its stake in DaVita Inc. (NYSE:DVA - Free Report) by 72.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,614 shares of the company's stock after selling 33,743 shares during the quarter. Cinctive Capital Management LP's holdings in DaVita were worth $1,930,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. lifted its holdings in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Copia Wealth Management bought a new stake in shares of DaVita in the 4th quarter worth about $30,000. National Pension Service increased its position in shares of DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in shares of DaVita during the 1st quarter valued at about $35,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of DaVita in the 1st quarter worth approximately $83,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Price Performance

Shares of NYSE:DVA traded down $3.26 during midday trading on Wednesday, reaching $133.45. 163,440 shares of the company's stock were exchanged, compared to its average volume of 849,485. The company's 50 day simple moving average is $139.04 and its two-hundred day simple moving average is $141.73. The firm has a market capitalization of $9.54 billion, a PE ratio of 13.11, a price-to-earnings-growth ratio of 0.96 and a beta of 1.13. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The business had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm's revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the company posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently commented on DVA shares. Barclays cut their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. Bank of America dropped their price objective on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research note on Wednesday. Finally, Truist Financial set a $148.00 price objective on shares of DaVita in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus price target of $158.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.